blde-20260528
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
May 28, 2026
Date of Report (date of earliest event reported)
___________________________________
STRATA CRITICAL MEDICAL, INC.
(Exact name of registrant as specified in its charter)
___________________________________
Delaware (State or other jurisdiction of incorporation or organization) | 001-39046 (Commission File Number) | 84-1890381 (I.R.S. Employer Identification Number) | ||||||
666 Third Avenue, 25th Floor New York, NY 10017 | ||||||||
(Address of principal executive offices and zip code) | ||||||||
(917) 781-3190 | ||||||||
(Registrant's telephone number, including area code) | ||||||||
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||
Securities registered pursuant to Section 12(b) of the Act: | ||||||||
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Common Stock, par value $0.0001 per share | SRTA | The Nasdaq Stock Market | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 - Submission of Matters to a Vote of Security Holders.
On May 28, 2026, Strata Critical Medical, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The proposals are described in the Company’s definitive proxy statement for the Annual Meeting, as filed with the Securities and Exchange Commission on April 14, 2026. The final results for the votes regarding each proposal are set forth below.
1.The Company’s stockholders elected the two (2) Class II directors listed below to the Board of Directors of the Company to hold office until the 2029 annual meeting of stockholders and until their respective successors have been duly elected and qualified. The votes regarding this proposal were as follows:
For | Withhold | Broker Non-Votes | ||||||||||||||||||
William A. Heyburn | 46,050,902 | 505,421 | 12,687,496 | |||||||||||||||||
Andrew Lauck | 39,525,159 | 7,031,164 | 12,687,496 | |||||||||||||||||
2.The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes regarding this proposal were as follows:
For | Against | Abstain | ||||||||||||
58,946,832 | 65,815 | 231,172 | ||||||||||||
3.The Company's stockholders approved, on an advisory, non-binding basis, the compensation of the Company's named executive officers (the "Say-on-Pay" vote). The votes regarding this proposal were as follows:
For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
38,497,962 | 8,022,682 | 35,679 | 12,687,496 | |||||||||||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STRATA CRITICAL MEDICAL, INC. | ||||||||||||||
Date: June 3, 2026 | By: | /s/ William A. Heyburn | ||||||||||||
Name: | William A. Heyburn | |||||||||||||
Title: | Co-Chief Executive Officer and Chief Financial Officer | |||||||||||||